HBV-IN-39-d3
Selected Variant
HY-156703S
Size: 1 mg
HBV-IN-39-d3 (Example 14) is a deuterated HBV-IN-39 (Example 13) . HBV-IN-39 is an HBV inhibitor. HBV-IN-39-d3 has better oral bioavailability than HBV-IN-39[1].
Product Specifications
CAS Number
2173356-23-3
UNSPSC
12352005
Target
HBV
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Solubility
10 mM in DMSO
Smiles
FC1=C2C3=CC(OC([2H])([2H])[2H])=C(OCCCOC)C=C3C[C@H](N2C=C(C1=O)C(O)=O)C(C)(C)C
Molecular Formula
C23H25D3FNO6
Molecular Weight
436.49
References & Citations
[1]Yi Chen, et al. Therapeutic agents for the treatment of HBV infection. Patent CN110240596B.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Price
Sign In for Pricing
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400499-500 1x 500 µL
Cytokeratin 14 (LL002), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470631-500 1x 500 µL
Human Lambda Light Chain (LcN-2), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681484-500 1x 500 µL
DOG-1 / TMEM16A (Gastrointestinal Stromal Tumor Marker) (DG1/1484), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC402223-500 1x 500 µL
Annexin A1 / (Hairy Cell Leukemia Marker) (CPTC-ANXA1-1), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details